Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — Cash Flow Quality Index

Latest as of June 2026: -0.04x

Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Cash Flow Quality Index of -0.04x as of June 2026. Operating cash flow of $-172.75K is below net income of $4.40 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Drugs Made In America Acquisition II Cor cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

-0.04x
Operating CF / Net Income

Operating Cash Flow

$-172.75K
USD

Net Income

$4.40 Million
USD

Data as of

Jun 2026
Most recent filing

Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow Quality Index (2025–2025)

Historical Cash Flow Quality Index for Drugs Made In America Acquisition II Corp. Ordinary Shares across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Drugs Made In America Acquisition II Cor cash conversion from operations.

Annual Cash Flow Quality Index for Drugs Made In America Acquisition II Corp. Ordinary Shares (2025–2025)

Year-by-year earnings quality comparison for Drugs Made In America Acquisition II Corp. Ordinary Shares.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 -0.24x $-1.02 Million $4.19 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.